{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:20:52Z","timestamp":1787656852051,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05067-7","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:47:37Z","timestamp":1773744457000},"page":"3491-3502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective comparative evaluation of clinical efficacy and safety of Intravesical gemcitabine\u2013docetaxel versus BCG in adjuvant management of BCG-naive non-muscle invasive urothelial bladder cancer in Indian population"],"prefix":"10.1007","volume":"58","author":[{"given":"Aviral","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashasvi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujwal","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Data","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya Narayan","family":"Sankhwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"5067_CR1","unstructured":"EAU guidelines (2025). Edn. Presented at the EAU annual congress Madrid. ISBN 978-94-92671-29-5."},{"key":"5067_CR2","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F 2024 Global cancer observatory: cancer today. Lyon, France: international agency for research on cancer. Available from: https:\/\/gco.iarc.who.int\/today."},{"key":"5067_CR3","unstructured":"https:\/\/main.icmr.nic.in\/sites\/default\/files\/whats_new\/Draft_Consensus_Document_Urinary_Bladder_cancer.pdf."},{"issue":"2","key":"5067_CR4","first-page":"43","volume":"22","author":"RS Matulewicz","year":"2020","unstructured":"Matulewicz RS, Steinberg GD (2020) Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol 22(2):43\u201351","journal-title":"Rev Urol"},{"issue":"13","key":"5067_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073","volume":"14","author":"S Jiang","year":"2022","unstructured":"Jiang S, Redelman-Sidi G (2022) BCG in bladder cancer immunotherapy. Cancers 14(13):3073","journal-title":"Cancers"},{"key":"5067_CR6","unstructured":"American Urological Association: BCG shortage notice. https:\/\/www.auanet.org\/practice-resources\/bcg-info\/bcg-shortage-notice"},{"issue":"7","key":"5067_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/life14070789","volume":"14","author":"M Bakula","year":"2024","unstructured":"Bakula M, Hudolin T, Knezevic N et al (2024) Intravesical gemcitabine and docetaxel therapy for BCG-na\u00efve patients: a promising approach to non-muscle invasive bladder cancer. Life 14(7):789. https:\/\/doi.org\/10.3390\/life14070789","journal-title":"Life"},{"issue":"2","key":"5067_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849","volume":"6","author":"IM McElree","year":"2023","unstructured":"McElree IM, Steinberg RL et al (2023) Comparison of sequential Intravesical gemcitabine and docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer. JAMA Netw Open 6(2):e230849","journal-title":"JAMA Netw Open"},{"key":"5067_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.09.004","author":"LJ Thomas","year":"2022","unstructured":"Thomas LJ, Steinberg RL et al (2022) Multi-institution evaluation of sequential Intravesical gemcitabine and docetaxel in the treatment of Bacillus Calmette-Guerin Na\u00efve patients with non-muscle invasive bladder cancer. Clinical Genitourin Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2022.09.004","journal-title":"Clinical Genitourin Cancer"},{"issue":"2","key":"5067_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.22037\/uj.v19i.7194","volume":"20","author":"A Ansari Djafari","year":"2023","unstructured":"Ansari Djafari A, Javanmard B et al (2023) Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the treatment of intermediate-risk non-muscle invasive bladder cancer: a randomized controlled trial. Urol J 20(2):123\u2013128. https:\/\/doi.org\/10.22037\/uj.v19i.7194","journal-title":"Urol J"},{"key":"5067_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001008640.01272.9d.19","author":"R Ben-David","year":"2024","unstructured":"Ben-David R, Alerasool P, Kolanukuduru KP, Tillu N, Eisenhauer J, Waingankar N et al (2024) MP16\u201319 comparison of BCG to gemcitabine\/docetaxel in the intermediate risk group composed mostly of TaHG. J Urol. https:\/\/doi.org\/10.1097\/01.JU.0001008640.01272.9d.19","journal-title":"J Urol"},{"issue":"3","key":"5067_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/MOU.0000000000001065","volume":"33","author":"T Kawada","year":"2023","unstructured":"Kawada T, Yanagisawa T, Araki M, Pradere B, Shariat SF (2023) Sequential Intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Curr Opin Urol 33(3):211\u2013218. https:\/\/doi.org\/10.1097\/MOU.0000000000001065","journal-title":"Curr Opin Urol"},{"issue":"1","key":"5067_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/JU.0000000000003977","volume":"212","author":"SH Patel","year":"2024","unstructured":"Patel SH, Gabrielson AT, Chan S et al (2024) A phase 2 trial of Intravesical gemcitabine and docetaxel in the treatment of Bacillus Calmette-Gu\u00e9rin\u2012na\u00efve nonmuscle-invasive urothelial carcinoma of the bladder. J Urol 212(1):95\u2013103. https:\/\/doi.org\/10.1097\/JU.0000000000003977","journal-title":"J Urol"},{"key":"5067_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.urology.2024.06.020","volume":"192","author":"JM Refugia","year":"2024","unstructured":"Refugia JM, Roebuck E, Thakker P et al (2024) Sequential Intravesical chemotherapy for treatment na\u00efve, high-risk non-muscle invasive bladder cancer: oncologic outcomes, tolerance, and comparison to contemporary controls. Urology 192:61\u201366. https:\/\/doi.org\/10.1016\/j.urology.2024.06.020","journal-title":"Urology"},{"issue":"8","key":"5067_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1159\/000524098","volume":"106","author":"T Pareek","year":"2022","unstructured":"Pareek T, Parmar K, Sharma AP, Kumar S (2022) Quality of life, efficacy, and safety of sequential Intravesical gemcitabine + docetaxel versus BCG for non-muscle invasive urinary bladder cancer: a pilot study. Urol Int 106(8):784\u2013790","journal-title":"Urol Int"},{"key":"5067_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.006","volume":"78","author":"JY Teoh","year":"2020","unstructured":"Teoh JY et al (2020) Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol 78:893","journal-title":"Eur Urol"},{"key":"5067_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16645","author":"P Scilipoti","year":"2025","unstructured":"Scilipoti P, Longoni M, de Angelis M et al (2025) Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. BJU Int. https:\/\/doi.org\/10.1111\/bju.16645","journal-title":"BJU Int"},{"issue":"1","key":"5067_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.euf.2024.09.006","volume":"11","author":"KP Kolanukuduru","year":"2024","unstructured":"Kolanukuduru KP, Ben-David R, Lidagoster S, Almoflihi M, Tillu N, Eraky A, Alerasool P, Waigankar N, Attalla K, Mehrazin R, Wiklund P, Sfakianos JP (2024) Comparative effectiveness of Bacillus Calmette-Gu\u00e9rin and sequential Intravesical gemcitabine and docetaxel for treatment-na\u00efve intermediate-risk non\u2013muscle-invasive bladder cancer. Eur Urol Focus 11(1):142\u2013149. https:\/\/doi.org\/10.1016\/j.euf.2024.09.006","journal-title":"Eur Urol Focus"},{"key":"5067_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688","author":"RL Steinberg","year":"2020","unstructured":"Steinberg RL, Thomas LJ, Brooks N et al (2020) Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000000688","journal-title":"J Urol"},{"issue":"3","key":"5067_CR20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/ijc.IJC_59_21","volume":"58","author":"M Vashist","year":"2021","unstructured":"Vashist M, Sinha S, Singh M, Saini A (2021) Immunological profile and nutritional status in Indian cancer patients: a concern for immunotherapy? Indian J Cancer 58(3):326\u2013331","journal-title":"Indian J Cancer"},{"issue":"2","key":"5067_CR21","first-page":"174","volume":"81","author":"NP Gupta","year":"2008","unstructured":"Gupta NP, Yadav R, Hemal AK, Dogra PN (2008) Clinical profile of carcinoma in situ of urinary bladder in India: rare presentation or underdiagnosed entity? Urol Int 81(2):174\u2013178","journal-title":"Urol Int"},{"issue":"1","key":"5067_CR22","first-page":"34","volume":"11","author":"A Ramaswamy","year":"2022","unstructured":"Ramaswamy A, Mangukiya R, Thomas A, Vora A (2022) Tolerability profile of Intravesical therapies in NMIBC: experience from a tertiary care center. South Asian J Cancer 11(1):34\u201338","journal-title":"South Asian J Cancer"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05067-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05067-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05067-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:40:38Z","timestamp":1787654438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05067-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5067"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05067-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8226998\/v1","asserted-by":"object"}]},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}